NCT07314138Recruiting
Multivessel Minimally Invasive Coronary Bypass Grafting as HYBRID Revascularization Versus Conventional Off-pump Coronary Artery Bypass Grafting
MICRA-HYBRID Trial: A Randomized Controlled Trial of 'Multivessel Minimally Invasive Coronary Bypass Grafting as HYBRID Revascularization Versus Conventional Off-Pump Coronary Artery Bypass Grafting'
Source: ClinicalTrials.gov · Last updated 27 Aug 2026
Brief summary (registry, in English)
The MICRA-HYBRID trial is a prospective, multicenter, randomized controlled study comparing multivessel hybrid coronary revascularization (HCR) as minimally invasive arterial bypass grafting to left-sided coronary targets (LAD and LCx) plus PCI of the RCA versus conventional off-pump coronary artery bypass grafting (OPCAB) via median sternotomy in patients with three-vessel coronary artery disease. The primary goal is to evaluate whether multivessel-HCR provides superior 30-day "textbook" clinical outcomes (mortality, MI, stroke, re-exploration for bleeding, and other complications) while improving perioperative recovery and long-term cardiovascular outcomes.
- Status (registry)
- Recruiting
- Study type
- Interventional
- Enrollment
- 250 (estimated)
- First submitted
- 3 Dec 2025
- Start date
- 25 Aug 2026
- Primary completion date
- 1 May 2029
- Lead sponsor
- Catharina Ziekenhuis Eindhoven
- Diseases
- Coronary artery disease
- NCT number
- NCT07314138
What you commit to
- Study type: Interventional
- Planned participants: 250
- From 25 Aug 2026 to the primary completion date, 1 May 2029
- 2 sites in 2 countries
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- RCA stenosis with high-risk clinical features requiring urgent PCI or surgical revasculari-zation.
- Reverse hybrid coronary revascularization, defined as PCI-RCA followed by surgical re-vascularization.
- Indication for concomitant cardiac surgery (e.g. valve or arrhythmia surgery) or non-cardiac surgery
- Previous thoracic or cardiac surgery, mediastinal irradiation, significant trauma to the chest
Other illness
- Acute cardiac ischemia necessitating immediate intervention.
- Preoperative severe end-organ dysfunction (dialysis, liver failure, respiratory failure) or cancer.
- History of pericarditis
Lab values
- eGFR \< 30 ml/min
Age
- Age \< 18 or \> 85 years
Other
- A potential participant who meets any of the following criteria will be excluded from participation in this study:
- Chronic total occlusion of the RCA
- In-stent RCA restenosis
- EF \< 30 %
- Hemodynamically significant left subclavian stenosis
- Severe chest wall deformities
- Body mass index \> 40 Kg/m2.
Who the study is looking for
- Patients with three-vessel disease (either angiographic stenoses \>70% or a fractional flow reserve value ≤0.80)
- Left main diameter stenosis ≥50% or a left main intravascular ultrasound minimal luminal area of ≤4.5 mm2 or fractional flow reserve value ≤0.80 combined with significant CAD of the right coronary artery
Age in the registry: 18 years to 85 years · Sex: All · Accepts healthy volunteers
Sites (2)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| University Hospitals Leuven Coordinator of this site? Confirm its status | Leuven | Belgium | Recruiting |
| Catharina Hospital Eindhoven Coordinator of this site? Confirm its status | Eindhoven | Netherlands | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.